Abstract:
Google Health and women’s health platform Flo Health announced a multi-year strategic partnership, accompanied by Google’s strategic investment in Flo. The two parties plan to interconnect Flo menstrual cycle records with wearable device data in Google Health starting in early 2027, with explicit authorization from users, to provide more coherent health information for different stages such as menstruation, pregnancy preparation, pregnancy and perimenopause. Flo said its platform has more than 80 million monthly active users and has been downloaded 500 million times.
According to the plan announced by both parties, users can choose to connect Flo with their Google Health account. The cycle information recorded by Flo can be combined with indicators such as resting heart rate, heart rate variability, skin temperature, and sleep stages in Google Health; Google Health data can also be provided to Flo in reverse, helping applications combine signals such as sleep, heart rate, respiratory rate, and temperature to adjust cycle predictions and symptom insights. Relevant data can come from devices such as Google Fitbit Air, Pixel Watch 5 and the new Fitbit Edge. The two parties have not disclosed the complete list of regions and devices supported by the first batch of synchronization functions.
Flo data will also be connected to Google Health Coach to provide users with personalized guidance based on cycle, sleep and recovery status; this service requires a separate subscription to Google Health Premium. Google emphasizes that cycle prediction and women's health functions are general health information and are not used for contraception, pregnancy preparation or other medical purposes, and should not replace a doctor's diagnosis. The two parties also plan to conduct women's health research and collaborate to develop new products that integrate Flo's health algorithms with Google wearable devices and sensors; no product form or launch time has been announced yet. Research interests may involve perimenopause, pregnancy and postpartum recovery, and symptom patterns in conditions such as polycystic ovary syndrome, endometriosis and uterine fibroids. Flo said that the research will use aggregated, de-identified or synthetic data and conduct clinical evaluation; the relevant goals are still part of the research and development plan and do not represent existing diagnostic tools or clinical results.
The two companies said that data exchange will adopt an itemized authorization mechanism, and users must agree separately for different data types and purposes, and can also withdraw at any time; Google said that Flo data shared through its health platform will not be used for advertising, sale, or provided to other applications or developers. Given that both parties have been involved in women's health data privacy disputes, these commitments will also be the key to whether the cooperation can gain the trust of users. The U.S. Federal Trade Commission reached a final settlement in 2021 regarding Flo's sharing of user health data with third parties including Google, requiring Flo to obtain explicit consent before sharing health information and undergo an independent privacy review; this regulatory process is different from the authorization mechanism of this new cooperation, but it highlights the protection issue of sensitive periodic data.
Comments